Navigation Links
PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity
Date:12/11/2007

Data Presented at the American Society of Hematology (ASH) Annual Meeting

Publication Number: 840

CHESHIRE, Conn., Dec. 11 /PRNewswire-FirstCall/ -- Soliris(R) (eculizumab) therapy reduced hemolysis, fatigue, thromboses (blood clots) and transfusion requirements in patients with a rare blood disorder called paroxysmal nocturnal hemoglobinuria (PNH), including those who might have been expected to have less severe disease, according to data from an ongoing open-label clinical study presented today at the 49th Annual Meeting of the American Society of Hematology Meeting in Atlanta.

The data were highlighted in an oral presentation titled, "High Incidence of Progression to Significant Disease Burden in Paroxysmal Nocturnal Hemoglobinuria Patients with Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion: Clinical Improvement with Eculizumab Therapy."

In the study, (1) Soliris was associated with significant long-term clinical improvements in patients with PNH, regardless of baseline degree of hemolysis, anemia or transfusion requirements. The study also demonstrated that patients who might have been expected to have less severe disease, considering their baseline clinical characteristics, suffered from significant disease burden.

"PNH patients once thought to have less severe disease based on their clinical characteristics actually face significant disease burden from anemia, fatigue, impaired quality of life, blood transfusion requirements and blood clot risk," said Monica Bessler, MD, PhD, lead author of the study and Professor of Medicine, Professor of Pharmacology and Molecular Biology, Washington University in St. Louis School of Medicine. "The results presented today show that, in this study group, regardless of disease severity, long- term Soliris treatment provides important clinical improvements in their disease signs, symptoms and complications."

"We continue to observe that the PNH
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. Many Heart Attack Patients Dont Get Best Emergency Treatment
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
11. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014 Research and ... the addition of the "Investment Analysis of ... to their offering. ... in the US medical device sector identifies the ... and venture capital investments, and mergers and acquisitions. ...
(Date:12/22/2014)... CHESTERBROOK, Pa. and STOCKHOLM ... AB (publ) (Sobi) and partner Auxilium Pharmaceuticals, Inc. today ... Use (CHMP) of the European Medicines Agency (EMA) has ... (collagenase clostridium histolyticum) for the treatment of adult men ... deformity of at least 30 degrees at the start ...
(Date:12/22/2014)... PALO ALTO, Calif. , Dec, 22, 2014 ... of a Phase 2a study of lonafarnib in ...  The study was conducted at the National Institutes ... Bethesda, Maryland .  The double-blinded, randomized, placebo-controlled, ... 100 mg twice daily and 200 mg twice ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
... Aug. 23 Biopure Corporation,(Nasdaq: BPUR ) ... clinical,study protocol to the FDA for compassionate use ... States. The proposed open label,study would make Hemopure ... or potentially life threatening anemia on a compassionate ...
... Alfacell Corporation,(Nasdaq: ACEL ) today announced that ... (2007; Vol. 31, Issue 3: 663-669) reports that,ONCONASE(R) ... types and tumor cell lines. The observed antioxidant ... effect on cancer cells and,mechanistic synergism with other ...
Cached Medicine Technology:Biopure Seeks Compassionate Use Protocol for Treatment of Acute Anemia 2Biopure Seeks Compassionate Use Protocol for Treatment of Acute Anemia 3Paper in International Journal of Oncology Reports Alfacell's ONCONASE(R) Suppresses Intracellular Oxidative Stress 2Paper in International Journal of Oncology Reports Alfacell's ONCONASE(R) Suppresses Intracellular Oxidative Stress 3
(Date:12/22/2014)... FRIDAY, Dec. 19, 2014 (HealthDay News) -- U.S. and ... to caramel apples that has killed at least four ... Consumers should not eat any commercially produced, prepackaged caramel ... for Disease Control and Prevention said in a news ... 28 people had been infected with the outbreak strains ...
(Date:12/22/2014)... 2014 Physicians in China are most ... treatment of non-Hodgkin’s lymphoma (NHL), according to a new ... healthcare consulting firm. MabThera is the only biologic available ... common form of NHL. , According to Kantar Health’s ... incidence of NHL in China has been growing and ...
(Date:12/22/2014)... Colorado (PRWEB) December 22, 2014 Super ... Black Friday this year as the busiest day in ... other retailers, The Grass Station had a steady pre-Christmas ... holiday gifts, this past Saturday. , “I definitely intend ... 33-year-old Robert, a Denver resident who was enjoying The ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Only weeks ... southern and mid-western cities to have a battery manufacturer ... TalkLocal ( http://www.talklocal.com ) is launching in Henderson ... economy. , “A strong manufacturing sector is going ... founder Gurpreet Singh explained, “and TalkLocal works with small ...
(Date:12/22/2014)... In recognition of Veteran’s Day, Discount Labels ... a local organization that provides services to veterans and ... on a couple hundred acres in the hills of ... class fishing, hunting, hiking, horseback riding, 4-wheeling, skeet shooting, ... ago to support U.S. Service men and women, police ...
Breaking Medicine News(10 mins):Health News:CDC Warns of Listeria Danger From Caramel Apples 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 3Health News:Customers at Colorado’s Grass Station Say They’re Enjoying the Experience of Legally Purchasing Marijuana this Year to Give as Christmas Presents to Friends and Family 2Health News:TalkLocal Launches in Henderson Weeks Following New Megafactory, New Jobs Announcement 2Health News:Discount Labels Donates Portion of November Sales to Hero Reward Program 2
... Capital BlueCross announced today that it will cover an ... and those with individual coverage during the upcoming 2009-2010 flu ... to include this benefit. , , A ... October. Various clinical vaccine trials have begun, some under the ...
... NEW YORK, Sept. 16 Dr. Mark Hasten, chairman of the ... Kadish, M.D., as senior provost and chief operating officer for Touro ... http://www.flickr.com/photos/tourocollege/3923514965/ , , Touro is ... college was founded by Dr. Bernard Lander in 1970, originally as ...
... , FARMINGTON HILLS, Mich., Sept. ... stock and assets of GTL, Inc. dba as "Link to ... product and service offerings into CST to provide cost-effective personal ... and quality of life for older adults, the disabled and ...
... 20% of emergency room visits and 5% of ... first-line treatment option in patients with gastrointestinal bleeding, ... diagnostic and treatment method in patients with gastrointestinal ... incidence of rebleeding in patients with negative initial ...
... HEATHROW, Fla., Sept. 16 Cozmix, Inc., a sales ... beta release of SizeMix, the sales industry,s first point and ... forms a core component of Cozmix, SizeMix Process. , ... components necessary to complete a full internal review of a ...
... , BALTIMORE, Sept. 16 While most men ... likely unaware of other important statistics that could one day save ... and the National Football League (NFL) are teaming to encourage men ... of cancer death for American men. Men and their loved ones ...
Cached Medicine News:Health News:Capital BlueCross to Cover Administration Costs of H1N1 Vaccine for Fully-Insured Groups, Individuals This Flu Season 2Health News:Touro Appoints Alan Kadish, M.D., Senior Provost and Chief Operating Officer 2Health News:Touro Appoints Alan Kadish, M.D., Senior Provost and Chief Operating Officer 3Health News:Touro Appoints Alan Kadish, M.D., Senior Provost and Chief Operating Officer 4Health News:Critical Signal Technologies Acquires Link to Life to Grow Depth and Expertise in TeleHealth, Personal Emergency Response and Medical Monitoring Systems 2Health News:Critical Signal Technologies Acquires Link to Life to Grow Depth and Expertise in TeleHealth, Personal Emergency Response and Medical Monitoring Systems 3Health News:Sales Force Sizing and Resource Optimization Software Is the First of Its Kind to Enter the Market (Beta Release) 2Health News:Video: NFL Season Kicks Off With Campaign to 'Know Your Stats About Prostate Cancer' 2Health News:Video: NFL Season Kicks Off With Campaign to 'Know Your Stats About Prostate Cancer' 3Health News:Video: NFL Season Kicks Off With Campaign to 'Know Your Stats About Prostate Cancer' 4
Ballard trach care HMES and filters, tv 1500, HME with built-in flex tube...
... Portex® Thermovent® T helps provide protection to the ... small and extremely lightweight making it ideal for ... a high rate of heat and moisture recovery, ... ,All HMEs and filters have ISO standard ...
... protection to the exposed airway of the tracheostomy ... it ideal for active young children as well ... and moisture recovery, it ensures patient comfort and ... have ISO standard tapered ends to assure a ...
For use with: , pulmonary function testing , nebulizer compressors , humidifiers , concentrators , proximal pressure lines ...
Medicine Products: